Sermorelin vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | Substance P |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |